Skip to content

Natural Orifice Translumenal Endoscopic Surgery: Laparoscopic-Assisted Transvaginal Cholecystectomy

Natural Orifice Translumenal Endoscopic Surgery: Laparoscopic-Assisted Transvaginal Cholecystectomy

Status
Terminated
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00910325
Enrollment
3
Registered
2009-05-29
Start date
2008-11-30
Completion date
2012-08-31
Last updated
2012-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholelithiasis

Keywords

Female, Cholelithiasis, Natural Orifice Surgery, Laparoscopic- Assisted, Transvaginal

Brief summary

To determine the feasibility, safety, and efficacy of a novel minimally invasive approach to cholecystectomy and to establish a description of this novel translumenal technique in humans at this institution.

Interventions

PROCEDURELaparoscopic-assisted transvaginal cholecystectomy

Trans-vaginal Cholecystectomy with Laparoscopic Assistance

Sponsors

Massachusetts General Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
26 Years to 64 Years
Healthy volunteers
No

Inclusion criteria

* Females who are postmenopausal or who no longer wish to bear children * Females \>25 years old and \<65 years old * Diagnosis of biliary disease requiring cholecystectomy * American Society of Anesthesiology (ASA) Class I or II * Females who are able to understand and willing to sign an informed consent document

Exclusion criteria

* Pregnancy * BMI \>= 30 * Patients who are still interested in childbearing * Patients taking immunosuppressive medications or who are immunocompromised * Patients with acute cholecystitis or history of acute cholecystitis ( as defined by right upper quadrant pain with history of fevers and/or elevated white blood cell count and/or positive ultrasound findings, ie, gallbladder wall thickening or pericholecystic fluid) * Patients with suspicion of gallbladder cancer * Patients with history of previous open abdominal surgery * Patients with untreated common bile duct stones

Design outcomes

Primary

MeasureTime frame
The safety and efficacy of the procedureone year

Secondary

MeasureTime frame
Post-operative painone year
Time to return to workone year
Time to return to daily activitiesone year

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026